JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Suletud

SektorTervishoid

14.83 4.66

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.17

Max

14.92

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+14.37% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.36%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	44M 295M
Eelmine avamishind	10.17
Eelmine sulgemishind	14.83

Uudiste sentiment

By Acuity

24%

76%

58 / 347 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. mai 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. mai 2026, 18:37 UTC

Suurimad hinnamuutused turgudel

Senseonic Shares Slide on Underwritten Offering Price

1. mai 2026, 16:46 UTC

Suurimad hinnamuutused turgudel

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 20:42 UTC

Tulu

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. mai 2026, 19:18 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. mai 2026, 18:36 UTC

Tulu

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. mai 2026, 18:35 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. mai 2026, 18:28 UTC

Tulu

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. mai 2026, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Barclays Completes Acquisition of Best Egg

1. mai 2026, 18:04 UTC

Tulu

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. mai 2026, 17:30 UTC

Market Talk

Tulu

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. mai 2026, 17:28 UTC

Market Talk

Tulu

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. mai 2026, 17:21 UTC

Market Talk

Tulu

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. mai 2026, 17:19 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. mai 2026, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 16:15 UTC

Tulu

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1. mai 2026, 16:11 UTC

Market Talk

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1. mai 2026, 16:04 UTC

Tulu

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

14.37% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 14.37%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

58 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.